<DOC>
	<DOCNO>NCT02836418</DOCNO>
	<brief_summary>ATYR1940-C-006 multi-national , multicenter study conduct center United States ( US ) Europe participate Study ATYR1940-C-003 ( Stage 1 ) ATYR1940-C-004 ( i.e. , parent study ) .</brief_summary>
	<brief_title>Study Evaluate Long-Term Safety , Tolerability , Biological Activity ATYR1940 Patients With Limb Girdle Facioscapulohumeral Muscular Dystrophy</brief_title>
	<detailed_description>Study ATYR1940-C-006 multi-national , multi-center , open-label extension study design evaluate long-term safety , effect muscle , PD ATYR1940 patient LGMD2B FSHD previously treat Protocol ATYR1940-C-003 ( Stage 1 ) ATYR1940-C-004 ( i.e. , parent study ) . This study conduct study center patient enrol parent study . Patients complete treatment period parent study ; Investigator 's opinion , demonstrate acceptable tolerability ATYR1940 , consider Investigator compliant ATYR1940 study procedure , meet criterion ATYR1940 discontinuation eligible participation current study , contingent upon Investigator patient agreement continue ATYR1940 treatment . For first 12 week extension study , patient receive ATYR1940 high tolerate dose receive parent study ; dose adjustment allow 12-week period . After 12 week , patient demonstrate good tolerability , ATYR1940 dose may increase patient-specific basis Investigator 's discretion , consultation Sponsor Medical Monitor . ATYR1940 dose increase &gt; 3.0 mg/kg permissible . All patient receive ATYR1940 weekly basis study , regardless frequency dose parent study . ATYR1940 administer via IV infusion 90 minute . If medically indicate , infusion duration volume may adjust Investigator 's discretion consultation Medical Monitor Sponsor .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Facioscapulohumeral</mesh_term>
	<mesh_term>Muscular Dystrophies , Limb-Girdle</mesh_term>
	<criteria>1 . Enrolled complete treatment period parent study . 2 . Demonstrated , Sponsor 's Investigator 's opinion , acceptable tolerability ATYR1940 . 3 . In Investigator 's opinion , patient show acceptable compliance ATYR1940 study procedure parent study willing able comply procedure current study . 4 . Is , opinion Investigator Sponsor , suitable candidate continue ATYR1940 treatment . 5 . Provide write informed consent assent nature study explain prior performance researchrelated procedure . 1 . Is expect require treatment curcumin systemic albuterol ( intermittent inhale albuterol permissible ) study participation ; use product putatively enhance muscle growth ( e.g. , insulinlike growth factor , growth hormone ) activity ( e.g. , Coenzyme Q , Coenzyme A , creatine , Lcarnitine ) chronic basis ; statin treatment initiation significant adjustment statin regimen ( stable , chronic statin use permissible ) . 2 . Planned receive vaccination study participation . 3 . Abnormal baseline finding , medical condition ( ) , laboratory finding , Investigator 's opinion , might jeopardize patient 's safety decrease chance obtain satisfactory data need achieve objective study . 4 . Evidence clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , metabolic , dermatological , gastrointestinal disease , condition require immediate surgical intervention treatment may allow safe participation . 5 . If female childbearing potential ( premenopausal surgically sterile ) , positive pregnancy test entry unwilling use contraception time entry 3month Followup visit . Acceptable method birth control include abstinence , barrier method , hormone , intrauterine device . 6 . If male , unwilling use condom plus spermicide sexual intercourse time entry 1 month Followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>FSHD</keyword>
	<keyword>LGMD</keyword>
</DOC>